Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotic drugs that are dopamine D2 receptor blockers.
Tardive dyskinesia (TD) is an idiopathic, often irreversible, involuntary movement disorder reported in 20% of patients following prolonged exposure to dopamine receptor antagonist drugs. 1 The determinants of risk for TD remain largely undefined. A few studies provide indirect basic and clinical evidence implicating a genetic component in idiosyncratic extrapyramidal reactions to antipsychotic drugs. [7] [8] [9] [10] We and others previously demonstrated an association between TD and a serine to glycine polymorphism (ser9gly) in exon 1 of the dopamine D3 receptor gene (DRD3).
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The 5-HT2A receptor is a site of action for atypical antipsychotic agents and has been implicated in their added efficacy as well as their reduced extrapyramidal side effects profile. 2 Atypical antipsychotic agents such as clozapine 15, 16 and olanzapine, 17 have been shown to induce much lower rates of TD than conventional antipsychotic drugs and this has been attributed to a protective effect of their high 5-HT2 receptor blocking activity relative to D2 receptor blockade. 17 The 5-HT2A receptor is distributed in striatal brain areas that modulate motor activity 18 and has been shown to interact with dopaminergic neurotransmission in brain regions relevant to antipsychotic drug action. 19 Rodent studies suggest that high occupation of 5-HT2A receptors with lower D2 receptor occupancy might be involved in the absence of up-regulation of D2 receptors after treatment with atypical antipsychotic drugs. 20 This may be relevant to the documented lower rates of TD with atypical agents, given the classical hypothesis implicating D2 receptor supersensitivity with pathogenesis of druginduced TD. 21 Furthermore, pretreatment with atypical antipsychotic agents has been shown to reduce repetitive jaw movements in a rat model for TD 22 and 5-HT2A receptor antagonists have been shown to attenuate apomorphine-induced stereotypic oral movements in rats. 23 Finally, long-term elevations in 5-HT2A receptor binding and mRNA expression in neostriatal regions have been documented in response to ontogenetic loss of dopamine neurons following 6 hydroxydopamine administration, 24 suggesting that such changes may similarly be relevant to pathogenetic processes related to TD. Taken together, the above clinical and basic data suggest a protective role for 5-HT2A receptor blockade in TD. We hypothesized that a genetically variant 5-HT2A receptor may alter risk for TD in schizophrenia patients following chronic exposure to antipsychotic drugs.
The 5-HT2A receptor gene is located on chromosome 13q14-21. 25 A number of polymorphic sites have been described in the gene. [3] [4] [5] 26, 27 Three of these sites, T102C, A-1438G, and his452tyr, are common variations in the population. A number of studies have shown a small but significant contribution of the T102C and more recently the A-1438G polymorphisms, to risk for schizophrenia 6, 28, 29 but several other studies could not replicate these findings. [30] [31] [32] [33] A number of studies including a meta-analysis, have found association of the his452tyr polymorphism with response to clozapine in schizophrenia patients, 34, 35 whereas for the T102C polymorphism both positive 34 and negative results 35, 36 have been found. Given their respective localization, the A-1438G polymorphism may be expected to alter the transcriptional activity of the receptor whereas the silent T102C site is likely to reflect the impact of the promoter site through linkage disequilibrium. However, A-1438G was not found to affect promoter activity in HeLa cells 28 and correlations with receptor density are inconclusive. 31, 37 Further studies are required to establish the functional impact of these polymorphic sites.
Given the above, we sought to examine the possibility that these common 5-HT2A receptor gene polymorphic sites influence the tendency to express TD following prolonged antipsychotic drug exposure in schizophrenia patients. We studied schizophrenia patients with (n = 59) and without TD (n = 62), matched for antipsychotic drug exposure and other relevant variables, and 96 normal control subjects. As shown in Table 1 , there was a significant excess of 5-HT2A-102C alleles in schizophrenia patients with TD (62.7%) compared to patients without TD (41.1%) and normal controls (45.9%; 2 = 12.8, df = 2, P = 0.002). Comparing the patients with and without TD, the 5-HT2A-102C allele was associated with a significantly increased risk for TD ( 2 = 11.4, df = 1, P = 0.0008, OR 2.41, 95% CI 1.43-3.99). Genotype distribution among the three groups was also significantly different ( 2 = 13.3, df = 4, P = 0.01). There was a striking excess of 102CC geno- Table 1 5-HT2A, T102C and his452tyr allele and genotype frequencies in patients with chronic schizophrenia with and without TD and normal control subjects. (Because the T102C and A-1438G are in complete linkage disequilibrium, findings for T102C in the table represent both polymorphisms.) 35 Thus, findings regarding allele frequency and genotype distribution reported for the 5-HT2A-T102C polymorphism are identical in regard to the A-1438G polymorphism. In contrast, there was no genotypic or allelic association between the his452tyr polymorphism and tardive dyskinesia. Genotype distributions of the 5-HT2A T102C, his452tyr; and A-1438G polymorphisms were in accordance with Hardy-Weinberg equilibrium (P Ͼ 0.1 in all cases).
An ANCOVA analysis (controlling for age at first antipsychotic treatment) revealed a significant effect of 5-HT2A T102C (or A-1438G) genotype on AIMS trunk dyskinesia scores (F = 3.9; df = 2, 116; P = 0.02) and also on degree of incapacitation due to dyskinetic movements (F = 5.0; df = 2, 115; P = 0.006) (Figure 1) . Patients with the 102CC (−1438GG) genotype had the highest trunk dyskinesia scores and were scored as having the greatest degree of incapacitation due to their dyskinetic movements. There was no significant difference in AIMS scores on any of the sub-scales or in degree of incapacitation among the his452tyr genotypes. There were no differences in PANSS total or subscale scores among the T102C, A-1438G or his452-tyr genotypes nor in Simpson Angus scores (data available on request).
These findings support a significant contribution of the 5-HT2A receptor gene to susceptibility to TD in schizophrenia patients following chronic exposure to dopamine receptor antagonist drugs. Of the three genetic variations examined, the promoter A-1438G site and the intronic T102C site were found to be in complete linkage disequilibrium in our sample, in accordance with previous studies. 35, 38 These two sites showed association with TD whereas no association was noted for the his452tyr site. Patients carrying the T102C, CC genotype and the A-1438G, GG genotype had significantly higher AIMS trunk dyskinesia scores and more incapacitation due to their dyskinetic movements than patients with other genotypes. If replicated, this could suggest that receptor abundance (likely to be affected by the A-1438G polymorphism and reflected also in T10C through linkage disequilibrium), rather than receptor sequence variation may be relevant to risk for neuroleptic-induced TD.
Our findings are unlikely to be due to ethnic stratification. There was no significant difference in 5-HT2A-T102C and A-1438G allele frequency or genotype distribution between the Ashkenazi and non-Ashkenazi controls, schizophrenia patients without TD and schizophrenia patients with TD. The ethnic distribution of the control and schizophrenia groups was similar as was the gender distribution. The control group was older than 35 years and thus past the age of risk for schizophrenia. A high degree of matching was achieved between the schizophrenia patients with and without TD, thus controlling for other variables that might differentially predispose to TD. There was a Molecular Psychiatry small difference in age at first antipsychotic treatment. This variable has not generally been reported as predisposing to TD. However, analysis of covariance indicated that 5-HT2A-T102C and A-1438G alleles contributed to dyskinesia independently of the contribution of age at first antipsychotic treatment.
Our finding points to the possibility that genetically determined endogenous differences in the 5-HT2A receptor may underlie clinical differences in expression of TD following prolonged exposure to D2 receptor antagonist drugs. Replications confirming this finding in independent patient samples employing a similar design are needed. Direct testing of the hypothesis may be achieved by examining TD subjects carrying different 5-HT2A alleles for a differential effect of challenge studies using selective probes, as well as imaging studies seeking genetically determined selective alterations in radioligand binding (eg the 5-HT2A antagonist ketanserin).
Whereas TD is usually regarded as a unitary entity, its clinical manifestations and course show considerable heterogeneity. Previous studies have described two major subtypes with predominantly orofacial or limb-truncal presentations. [39] [40] [41] [42] Distinct clinical and demographic risk factors have been reported to associate with each of these subtypes suggesting that different etiological factors and pathogenetic mechanisms may be involved. [39] [40] [41] [42] Our results point to the possibility that the 5-HT2A polymorphic region may differentially modulate the risk for these TD subtypes with a specific emphasis on the trunk subtype.
Our results also raise the interesting possibility that the 5-HT2A receptor gene may contribute to the risk for a subtype of schizophrenia that shows predilection for drug-induced TD. Differential inclusion of patients with this subtype in study samples may explain why some studies have shown a small but significant contribution of the T102C, and more recently the A-1438G polymorphisms to risk for schizophrenia 6, 28, 29 while others could not replicate these findings. [30] [31] [32] [33] This subtype may also be differentially responsive to classical antipsychotic drugs and clozapine which would be in accordance with the variable results that have been obtained with regard to the T102C polymorphism and response to this atypical antipsychotic drug. [34] [35] [36] Inclusion of a refined subtype of schizophrenia patients may improve the specificity of the above findings, and reduce the variance of results obtained for a more generally defined schizophrenia phenotype.
The 5-HT2A receptor gene is likely to affect risk for TD in concert with other small effect genes such as DRD3, in the context of prolonged exposure to antipsychotic drugs that block dopamine receptors and other clinical and demographic risk factors. Elucidation of genetic factors that contribute to TD liability will facilitate prediction of the syndrome allowing rational costbenefit considerations in the choice of antipsychotic drug therapy and will contribute to our general understanding of the molecular genetic basis of complex phenotypes.
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Materials and methods
Subjects
The sample of patients and controls used for this study was essentially the same as that previously reported by us in relation to DRD3 and TD, 10 with slight differences in the number of subjects, due to technical reasons. Patients from the participating centers who fulfilled inclusion/exclusion criteria, were screened for TD, according to the Research Diagnostic Criteria for Tardive Dyskinesia (RDC-TD). 43 The inclusion criteria were: (1) Diagnosis of schizophrenia according to DSM-IV criteria; (2) age 18-65 years; (3) male or female; (4) lifetime duration of exposure to antipsychotic drugs of at least 5 years; (5) Jewish, of definite Ashkenazi or nonAshkenazi origin (ie both parents of Ashkenazi or nonAshkenazi origin); (6) stable dose of antipsychotic and anticholinergic medication for 3 months prior to evaluation; (7) willingness to participate in the study and to give written informed consent. Patients with a lifetime history of alcohol/substance dependence or of abuse within the last 5 years, active or past medical or neurologic illness that might confound study assessments or of mixed or uncertain ethnic origin, were excluded.
The TD (n = 59) and non-TD (n = 62) groups were matched on the following criteria: age (54.4 ± 13.0 vs 50.5 ± 10.2 years, P = 0.08), gender (50.8% vs 51.6% male, P Ͼ 0.1), ethnic origin (Ashkenazi 57.6% vs 59.7%, P Ͼ 0.1), years of antipsychotic treatment (range 2.5 years) (24.6 ± 11.5 vs 23.9 ± 10.8, P Ͼ 0.1), dose of antipsychotic medication during the preceding 3 months in chlorpromazine units (804.0 ± 874.6 vs 871.0 ± 811.2, P Ͼ 0.1) and lifetime history of cigarette smoking in pack years (40.2 ± 33.0 vs 36.6 ± 25.9, P Ͼ 0.1). Subjects were not matched a priori for age at first antipsychotic treatment and this variable also differed significantly between the TD and non-TD groups (28.2 ± 10.2 vs 24.2 ± 8.3; t = 2.4, df = 118, P = 0.02). Accordingly, age at first antipsychotic treatment was entered as a covariate in parametric analyses. The size of our sample is sufficient to detect a difference of 18% in allele frequency between patients with and without TD at an alpha of 0.05 (two-tailed) with a power of 80%.
Control subjects (n = 96, 54.1% male, 50.5% Ashkenazi) were recruited from neighborhood community centers and from the administrative, technical and service staff of the Hadassah-Hebrew University Medical Center. Personal and family history (in first degree relatives) of Axis I, DSM-IV psychiatric disorder was excluded by a screening interview. Only Jewish control subjects with clearly defined Ashkenazi or nonAshkenazi origin (both parents Ashkenazi or nonAshkenazi) who were older than 35 years, were included.
The study was approved by the Internal Review Board (Helsinki Committee) of the Hadassah-Hebrew University Medical Center and all subjects gave written informed consent.
Diagnostic instruments
Instruments of evaluation included standardized checklists for the diagnosis of schizophrenia according to DSM-IV on the basis of clinical examination and case notes, the Abnormal Involuntary Movement Scale (AIMS), 44 the Positive and Negative Symptom Scale (PANSS) 45 and the Simpson Angus scale 46 for extrapyramidal signs. To insure consistency in ratings of TD, all raters achieved inter-rater reliability of Ͼ0.90 with the investigator bearing overall responsibility for the TD assessments (UHL), based on the same series of patients, before commencing the study. Patients who received a rating of mild dyskinesia in two or more body areas or of moderate or severe dyskinesia in any body area on the basis of the AIMS were categorized as having TD according to RDC-TD. Patients were assessed only once. Therefore, the diagnosis of TD in our sample corresponds to the category termed 'crosssectional TD' by Steen et al. 12 
Genotyping
Genotyping of the 5-HT2A polymorphisms was performed by PCR-based restriction analysis, as previously described for the 5-HT2A T102C, 3 A-1438G 5 and his452tyr. 4 
Statistical analyses
The SAS program and Statistica for Windows were used for statistical analyses. There were no differences in allele frequency for the T102C, A-1438G and his452-tyr sites between subjects of Ashkenazi and non-Ashkenazi origin among the control and patient groups; therefore, the groups were combined for statistical analysis. Maximum likelihood chi-square statistics were used for categorical analyses. Differences between groups on continuous variables were evaluated by ttest, analysis of variance (ANOVA) or analysis of covariance (ANCOVA). Hardy-Weinberg equilibrium was calculated with the utility program of J Ott (http://linkage.rockefeller.edu/ott/linkutil.htm) and linkage disequilibrium with the EH program available from the same site. P values Ͻ0.05 for two-tailed tests were regarded as significant.
